CAS: 154-42-7; 2-Amino-3,7-Dihydro-6H-Purine-6-Thione

该化合物是一种合成的纯素类像,主要用于治疗某些类型的白血病和其他恶性肿瘤,是一种抗蛋白素,主要用于治疗某些类型的白血病和其他恶性肿瘤,其化学结构具有硫醇组,它与天然存在的核核糖核酸基有区别,众所周知,该化合物能够干扰核酸合成,从而抑制细胞扩散,特别是在快速分解的癌症细胞中.Tioguanine一般是口服的,在肝脏中代谢,肝脏中,它会转化成活性代谢剂,产生细胞毒性效应.重要的是,监测病人潜在的副作用,包括宫颈压,肝中毒和胃肠扰动.此外,硫酸可以与其他药物发生相互作用,因此需要仔细管理混合疗法.由于其行动机制,Thioguanine被归类为抗肾上腺素,并经常与其他止血代剂一起使用,以提高治疗效力.它的使用受特定剂量系统及病人的某种关键反应的治疗系统和治疗.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

2-amino-6-chloropurine guanine 2-amino-1,9-dihydro-6H-purin-6-one 9-(2,3-dideoxy-3-hydroxymethyl-α-D-erythro-pentofuranosyl)-6-thioguanine H-purin-2-ylamine6-ethylmercapto-7(9)H-purin-2-ylamine 6-Methylthioguanine 2-amino-6-chloropurine 2-Amino-6-hydrazino-7H-purine

合成工艺路线路线简述

    Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于氨,水体系中,化学反应生成6-硫鸟嘌呤
    参考文献:Mercapto Heterocycles And Method Of Making
    标题:Mercapto Heterocycles And Method Of Making

    专利信息


    专利号:US-2004242897-A1
    优先权日:2002-07-31
    标题 :Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:US-2015182634-A1
    优先权日:2012-12-28
    标 题:Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action
    发明人:COYNE CODY P; BEAR RYAN; JONES TONI
    权利人:COYNE CODY P; BEAR RYAN; JONES TONI
    摘要:Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma/carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma.

    专利号:US-2012177593-A1
    优先权日:2009-07-20
    标 题 :Synthesis of dendrimer conjugates
    发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
    权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
    摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

    专利号:WO-2004011474-A1
    优先权日:2002-07-31
    标题:Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K
    权利人:ISIS PHARMACEUTICALS INC; GUZAEV ANDREI P; MANOHARAN MUTHIAH; RAVIKUMAR VASULINGA T; KUMAR RAJU K
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotide and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:US-6653468-B1
    优先权日:2002-07-31
    标 题 :Universal support media for synthesis of oligomeric compounds
    发明人:GUZAEV ANDREI P; MANOHARAN MUTHIAH
    权利人:ISIS PHARMACEUTICALS INC
    摘要:Compounds for the synthesis of oligomeric compounds, particularly oligonucleotides and oligonucleotide mimetics, are provided. In addition, methods for functionalizing a support medium with a first monomeric subunit and methods for the synthesis of oligomeric compounds utilizing the novel compounds bound to support media are provided.

    专利号:US-2010137421-A1
    优先权日:2006-11-08
    标题 :Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
    发明人:THEODORAKIS EMMANUEL; BATOVA AYSE
    权利人:THEODORAKIS EMMANUEL; BATOVA AYSE
    摘要:Provided herein are compounds that are inducers of apoptosis activators of caspases and pharmaceutically acceptable derivatives thereof. Also provided are methods of synthesis of the compounds and methods for treatment of diseases in which there is uncontrolled cell growth and spread of abnormal cells, such as cancers, by administering the compounds.
    浙江奥翔药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.ausunpharm.com
    企业联系电话:0576-85589335👤
    📞浙江奥翔药业股份有限公司 ⚠️参考联系方式
    联系人:陶经理
    电话:0576-85589335

    传真:0086-576-85589168
    邮箱:sales@ausunpharm.com
    通信地址: 浙江省化学原料药基地临海园区东海第四大道5号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省化学原料药基地临海园区东海第四大道5号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    浙江诚意药业股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zjcyyy.com
    电话: 86-577-63483980 63487860 86-21-65228989👤
    📞浙江诚意药业股份有限公司 ⚠️参考联系方式

    销售电话:86-577-63483980 63487860 86-21-65228989
    邮箱:export@chengyipharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    三晶新材料科技(泰州)有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sanjingchem.com
    企业联系电话:0519-86644596 13852622638👤
    📞三晶新材料科技(泰州)有限公司 ⚠️参考联系方式
    联系人:程斌
    电话:0519-86644596 13852622638
    手机:13852622638
    传真:0519-82059062
    邮箱:sales@sanjingchem.com
    通信地址: 江苏省靖江市生祠镇红北路90号
    邮编:
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省靖江市生祠镇红北路90号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ren X, Xu YZ, Karran P. Photo-oxidation of 6-Thioguanine by UVA: The Formation of Addition Products with Low Molecular Weight Thiol Compounds. Photochem Photobiol. 2010 Jun 21. [Epub ahead of print] Epub 2009 Dec 21.
    3: Brem R, Li F, Karran P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res. 2009 Apr;37(6):1951-61. Epub 2009 Feb 10.
    4: Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol. 2008 Oct;66(4):517-28. Epub 2008 Jun 28.

    合成参考文献


    参考文献:10.1074/jbc.m110.101139
    摘要:An S, Kyoung M, Allen JJ, Shokat KM, Benkovic SJ. Dynamic Regulation of a Metabolic Multi-enzyme Complex by Protein Kinase CK2. Journal of Biological Chemistry. 2010 Apr;285(15):11093–9. doi: 10.1074/jbc.m110.101139.
    参考文献:10.1007/s13238-011-1056-8
    摘要:Qin L, Jin L, Lu L, Lu X, Zhang C, Zhang F, Liang W. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell. 2011 Jun;2(6):507–16.
    参考文献:10.1038/cddis.2011.62
    摘要:Zong D, Hååg P, Yakymovych I, Lewensohn R, Viktorsson K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation. Cell Death & Disease. 2011 Jul 21;2(7):e181. doi: 10.1038/cddis.2011.62.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知